FDA Rules Insufficient For Statins, Chronic Switches – Former NDAC Chair

Future attempts to switch drugs for chronic, asymptomatic conditions to OTC status could be stymied unless new authorities are granted to FDA, says the chairwoman who oversaw the most recent Nonprescription Drugs Advisory Committee meeting to review a statin switch application